Lipocine Inc. agreed with A.G.P./Alliance Global Partners to set the sales-agent fee on covered sales at up to 3.0%, subject to adjustment by both parties. The term gives investors a stated ceiling for agent compensation under the Sales Agreement dated Apr 26, 2024.

Key Highlights

  • Lipocine and A.G.P./Alliance Global Partners reached the agreement on Sep 8, 2026.
  • The fee can be adjusted by Lipocine and the sales agent.
  • President and CEO Mahesh V. Patel signed on behalf of Lipocine on Sep 11, 2026.

Lipocine Inc. (NASDAQ: LPCN) agreed to set the fee payable to A.G.P./Alliance Global Partners on covered sales at up to 3.0%. The arrangement applies to sales made under the Sales Agreement dated Apr 26, 2024, giving the sales agent’s compensation a stated ceiling.

The fee terms were agreed on Sep 8, 2026, between Lipocine and A.G.P./Alliance Global Partners, which serves as the sales agent under the arrangement. Lipocine and the sales agent may adjust the fee under the agreed terms, so the stated percentage is subject to changes by both parties. The terms identify the maximum fee as “up to” 3.0%, linking the percentage to the covered sales activity.

Investor Insights

Mahesh V. Patel, Lipocine’s president and chief executive officer, signed on behalf of the company on Sep 11, 2026.